Study entry criteria
Inclusion criteria |
| MM/NHL in 1st or 2nd CR or PR |
| Age, 18-70 y |
| ECOG performance status of 0 or 1 |
| Up to 3 prior chemotherapy regimens (thalidomide and dexamethasone were not considered chemotherapy for this purpose) |
| Resolution of all prior acute chemotherapy toxicities |
| WBC count greater than 3.0 × 109/L; ANC greater than 1.5 × 109/L; platelet count greater than 100 × 109/L |
| Cr no more than 195 μM |
| AST/ALT/bilirubin less than twice normal |
| LVEF greater than 45% |
| DLco greater than 45%, FEV1 greater than 50% predicted |
| HIV negative |
| Able to provide informed consent |
| For women, not being pregnant and being willing to use contraception |
| Exclusion criteria |
| High-risk comorbidities for acute treatment complications (eg, symptomatic coronary artery disease) |
| Residual acute conditions from prior chemotherapy |
| Brain metastases or carcinomatous meningitis |
| Acute infection or unexplained fever above 38°C |
| Hypercalcemia (0.25 mM above normal) |
| Weight greater than 150% of ideal weight |
| Experimental therapy within 4 wk |
| Recent cytokine administration (pegfilgrastim [Neulasta] within 21 d; other cytokines within 7 d) |
| For women, pregnancy or lactation |
| ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell; ANC, absolute neutrophil count; Cr, creatine; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LVEF, alanine aminotransferase; DLco, diffusing lung capacity for carbon monoxide; FEV1, forced expiratory volume in 1 second. |
Inclusion criteria |
| MM/NHL in 1st or 2nd CR or PR |
| Age, 18-70 y |
| ECOG performance status of 0 or 1 |
| Up to 3 prior chemotherapy regimens (thalidomide and dexamethasone were not considered chemotherapy for this purpose) |
| Resolution of all prior acute chemotherapy toxicities |
| WBC count greater than 3.0 × 109/L; ANC greater than 1.5 × 109/L; platelet count greater than 100 × 109/L |
| Cr no more than 195 μM |
| AST/ALT/bilirubin less than twice normal |
| LVEF greater than 45% |
| DLco greater than 45%, FEV1 greater than 50% predicted |
| HIV negative |
| Able to provide informed consent |
| For women, not being pregnant and being willing to use contraception |
| Exclusion criteria |
| High-risk comorbidities for acute treatment complications (eg, symptomatic coronary artery disease) |
| Residual acute conditions from prior chemotherapy |
| Brain metastases or carcinomatous meningitis |
| Acute infection or unexplained fever above 38°C |
| Hypercalcemia (0.25 mM above normal) |
| Weight greater than 150% of ideal weight |
| Experimental therapy within 4 wk |
| Recent cytokine administration (pegfilgrastim [Neulasta] within 21 d; other cytokines within 7 d) |
| For women, pregnancy or lactation |
| ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell; ANC, absolute neutrophil count; Cr, creatine; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LVEF, alanine aminotransferase; DLco, diffusing lung capacity for carbon monoxide; FEV1, forced expiratory volume in 1 second. |